Hematological Malignancies

Ibrutinib in B-cell lymphoma

Responders (n/N)

Mantle cell

7/9

CLL/SLL

11/16

FL

6/16

DLBCL

2/7 3/4

WM ORR

60% N=56. Median 3 (1-10) prior therapies

Advani R H et al. JCO 2013;31:88-94